NLRP3 and COVID-19: This elaborate mechanism, together with our in vivo study, jointly supported the promise of the NLRP3 inflammasome as a valid target in treating COVID-19 related immune activation although we did not perform an assay to verify the binding of NLPR3 with ASC in our system.